Treatment options for
metastatic urothelial carcinoma:

News

Provided by our news bureau, medwireNews, our conference coverage is a useful resource for healthcare practitioners to keep up to date with the latest medical news. Stay informed on the recent advances and clinical developments presented at key congresses, by watching leading experts analyze the key results and discussing the latest research studies in our videos below.

Our conference coverage from the ASCO 22 Annual Meeting, ESMO and ASCO GU is now available to view here.

Article: JAVELIN Bladder 100 exploratory analyses point to wide use of maintenance avelumab

Conference Coverage from ASCO 22 Annual Meeting

Video: EV-301 update reinforces third-line enfortumab vedotin benefit in advanced UC

Conference Coverage from ASCO 22 Annual Meeting

Video: ATLANTIS rules out cabozantinib as a maintenance option for mUC

Conference Coverage from ASCO 22 Annual Meeting

Video: COSMIC-021 cohorts continue to show encouraging cabozantinib–atezolizumab advanced UC activity

Conference Coverage from ASCO 22 Annual Meeting

Article: No benefit of maintenance cabozantinib in unselected patients with mUC

Conference Coverage from ASCO 22 Annual Meeting

Article: Enfortumab vedotin offers sustained benefit over 2 years in advanced UC

Conference Coverage from ASCO 22 Annual Meeting

Article: More support from COSMIC-021 for cabozantinib–atezolizumab potential in advanced UC

Conference Coverage from ASCO 22 Annual Meeting

Video: First-line avelumab investigated in cisplatin-unfit advanced UC patients.

Conference Coverage from ASCO GU

Video: Potential of sacituzumab govitecan plus pembrolizumab demonstrated in mUC patients.

Conference Coverage from ASCO GU

Article: Maintenance rucaparib feasible for platinum-responsive mUC with DRD biomarkers.

Conference Coverage from ASCO GU

Article: Sacituzumab govitecan–pembrolizumab combo encouraging for pretreated mUC.

Conference Coverage from ASCO GU

Article: BAYOU hints at potential of durvalumab–olaparib in mutated metastatic UC.

Conference Coverage from ASCO GU

Article: Maintenance niraparib fails to improve advanced urothelial cancer PFS.

Conference Coverage from ASCO GU

Video: ATLANTIS points to maintenance benefit of rucaparib in mUC.

Conference Coverage from ASCO GU

News and expert video interviews from the ESMO Congress.​

Conference Coverage from ESMO Congress